Tomtovok afatinib: Additional Phase II data

Additional data from the open-label, single-arm, U.S. and Taiwanese Phase II LUX-Lung 2 trial in 129 patients showed that afatinib as first- or second-line therapy led to OS and PFS of 24 and 14 month...